Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention: An Analysis From the National Cardiovascular Data Registry [Pharmacology]

Conclusions—
In patients with end-stage renal disease undergoing PCI, bivalirudin and UFH were used with similar frequency although the patterns of use changed over the enrollment period. Patients with end-stage renal disease undergoing PCI had a lower adjusted risk of in hospital outcomes with bivalirudin; however, given the observational nature of this analysis, a randomized trial is warranted.

Source: Circulation: Cardiovascular Interventions - February 5, 2018 Category: Cardiology Authors: Washam, J. B., Kaltenbach, L. A., Wojdyla, D. M., Patel, M. R., Klein, A. J., Abbott, J. D., Rao, S. V. Tags: Anticoagulants, Percutaneous Coronary Intervention, Pharmacology Source Type: research